|Table of Contents|

Analysis of screening effect of common cervical cancer screening methods in cervical adenocarcinoma in situ

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 08
Page:
1518-1523
Research Field:
Publishing date:

Info

Title:
Analysis of screening effect of common cervical cancer screening methods in cervical adenocarcinoma in situ
Author(s):
DU Yushu; ZHANG Danye; ZHANG Dandan; LI Hexiao; QI Yue; LIU Juanjuan; YE Qiulin; DONG Hui; ZHANG Liyang; LIN Bei
Department of Gynecology and Obstetrics，Affiliated Shengjing Hospital of China Medical University，Liaoning Shenyang 110004，China.
Keywords:
cervical adenocarcinoma in situ; HPV test; cytology screening; endocervical curettage
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2023.08.024
Abstract:
Objective:To explore the screening effect of common cervical cancer screening methods on cervical adenocarcinoma in situ (AIS).Methods:A total of 127 patients with AIS in our hospital were selected and their clinical manifestations and diagnostic approaches were retrospectively analyzed.According to the final diagnosis of squamous intraepithelial lesions,127 patients were divided into pure AIS group (n=49) and AIS+CIN group (n=78).Results:Of the 127 patients,82(64.6%) had no clinical symptoms,and the common clinical symptoms in the remaining cases were postcoital bleeding (25.2%,32/127),irregular vaginal bleeding (9.4%,12/127),vaginal discharge (3.9%,5/127).HPV testing was performed in 120 of 127 patients.95.8%(115/120) of AIS patients had positive results of HPV tests.93.3%(42/45) in pure AIS group had positive results of HPV tests.The most common single HPV infection types were HPV16,18 and 45.Among the 111 cases with positive HPV subtyepe results,106 cases (95.5%) had HPV16 or (and) 18 infection,and 110 cases (99.1%) had HPV16 or(and) 18 or(and) 45 infection.Cytology tests were performed in 98 of 127 patients.37.8%(37/98) of cases show normal.49.0%(48/98) of cases show squamous epithelial abnormalities and only 13.3%(13/98) show glandular epithelial abnormalities.HPV tests combined with cytology screenings were completed in 93 of 127 patients and positive results were observed in 91 patients (97.8%),including 94.1%(32/34) of patients in the pure AIS group and 100%(59/59) of patients in the AIS+CIN group (P=0.13).The screening rate of AIS by HPV tests combined with cytology screenings were not significantly different from that by HPV tests alone (P=0.13),but were significantly higher than that by cytology screening alone (P＜0.01).Cervical surface biopsies were performed in 122 of 127 patients,of whom 97 (79.5%) had AIS lesions.57 patients underwent endocervical curettage (ECC),of whom 21(36.8%) had AIS lesions.There was no significant difference in the detection rate of AIS in cases who underwent only cervical surface biopsy compared to those who underwent both ECC and cervical surface biopsy (P=0.13).Conclusion:HPV typing tests combined with cytological screening can screen AIS cases effectively.

References:

［1］刘萍.中国大陆13年宫颈癌临床流行病学大数据评价［J］.中国实用妇科与产科杂志,2018,34(01):41-45. LIU P.Big data evaluation of the clinical epidemiology of cervical cancer in China's mainland［J］.Chinese Journal of Practical Gynecology and Obstetrics,2018,34(01):41-45.
［2］CLEVELAND AA,GARGANO JW,PARK IU,et al.Cervical adenocarcinoma in situ:Human papillomavirus types and incidence trends in five states,2008-2015［J］.Int J Cancer,2020,146:810-818.
［3］HEPLER TK,DOCKERTY MB,RANDALL LM.Primary adenocarcinoma of the cervix［J］.Am J Obstet Gynecol,1952,63:800-808.
［4］KURMAN RJ,CARCANGIU ML,CS H.WHO classification of tumors of female reproductive organs［M］.Lyon:International Agency for Research on Cancer,2014:169-206.
［5］金俊,罗荣奎,赵婧,等.宫颈原位腺癌人乳头状瘤病毒感染情况及分型分析［J］.中华病理学杂志,2022,51(04):338-343. JIN J,LUO RK,ZHAO J,et al.Colposcopic image analysis of cervical glandular epithelial lesions［J］.Chinese Journal of Pathology,2022,51(04):338-343.
［6］马晓欣,向阳,刘从容,等.子宫颈原位腺癌诊断与管理的中国专家共识（2021年版）［J］.中国实用妇科与产科杂志,2021,37(12):1209-1213. MA XX,XIANG Y,LIU CR,et al.Chinese experts' consensus on diagnosis and management of cervical adenocarcinoma in situ (2021 edition)［J］.Chinese Journal of Practical Gynecology and Obstetrics,2021,37(12):1209-1213.
［7］ VERDOODT F,JIANG X,WILLIAMS M,et al.High-risk HPV testing in the management of atypical glandular cells:A systematic review and meta-analysis［J］.Int J Cancer,2016,138:303-310.
［8］HOLL K,NOWAKOWSKI AM,POWELL N,et al.Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias:Results from a European multinational epidemiological study［J］.Int J Cancer,2015,137:2858-2868.
［9］CHEN W,MOLIJN A,ENQI W,et al.The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma:A hospital based nation-wide multi-center retrospective study across China［J］.Int J Cancer,2016,139:2687-2697.
［10］ZHAO C,CROTHERS BA,TABATABAI ZL,et al.False-negative interpretation of adenocarcinoma in situ in the college of American Pathologists Gynecologic PAP Education Program［J］.Arch Pathol Lab Med,2017,141:666-670.
［11］XU MY CB,CHEN Y,DU J,et al.Prevalence and type distribution of human papillomavirus in a Chinese urban population between 2014 and 2018:a retrospective study［J］.Peer J,2020,8:e8709.
［12］李娟,孙小荣,赵澄泉,等.子宫颈腺癌筛查面临的挑战［J］.中国妇产科临床杂志,2020,21(02):212-215. LI J,SUN XR,ZHAO CQ,et al.Challenges of cervical adenocarcinoma screening［J］.Chinese Journal of Clinical Obstetrics and Gynecology,2020,21(02):212-215.
［13］龚子元,俞梅,沈铿,等.宫颈原位腺癌诊治研究进展［J］.中国实用妇科与产科杂志,2019,35(11):1278-1281. GONG ZY,YU M,SHEN J,et al.Advances in diagnosis and treatment of cervical adenocarcinoma in situ［J］.Chinese Journal of Practical Gynecology and Obstetrics,2019,35(11):1278-1281.
［14］余小琴,江蓓蕾,方勇.DNA倍体分析联合高危型HPV检测预测宫颈上皮内瘤变［J］.中华妇产科杂志,2013,48(06):459-461. YU XQ,JIANG BL,FANG Y.Prediction of cervical intraepithelial neoplasia by DNA ploidy analysis combined with high-risk HPV detection［J］.Chinese Journal of Practical Gynecology and Obstetrics,2013,48(06):459-461.
［15］梁羽飞,韦晓芳,褚伯良,等.宫颈脱落细胞DNA定量分析对宫颈病变高危型HPV初筛阳性患者分流的价值［J］.浙江医学,2020,42(02):154-156，160. LIANG YF,WEI XF,CHU BL,et al.The value of DNA quantitative analysis of cervical exfoliated cells in the triage of high-risk HPV positive patients with cervical lesions［J］.Zhejiang Medicine,2020,42(02):154-156,160.
［16］杨淑丽,赵静,吴玉梅,等.宫颈腺上皮病变的阴道镜图像分析［J］.中国医刊,2018,53(07):739-742. YANG SL,ZHAO J,WU YM,et al.Colposcopic image analysis of cervical glandular epithelial lesions［J］.China Med,2018,53(07):739-742.
［17］TAN JHJ,MALLOY MJ,THANGAMANI R,et al.Management and long-term outcomes of women with adenocarcinoma in situ of the cervix:A retrospective study［J］.Aust NZJ Obstet Gynaecol,2020,60(1):123-129.
［18］BAALBERGEN A,HELMERHORST TJ.Adenocarcinoma in situ of the uterine cervix:a systematic review［J］.Int J Gynecol Cancer,2014,24:1543-1548.

Memo

Memo:
盛京自由研究者计划(编号:201804)
Last Update: 1900-01-01